premenstrual%20dysphoric%20disorder
PREMENSTRUAL DYSPHORIC DISORDER
Premenstrual dysphoric disorder is a cyclical disorder presenting with distressing mood and behavioral symptoms that occur during the late luteal phase of the ovulatory cycle; it is a severe form of premenstrual syndrome.
It results in considerable impairment of the patient's personal functioning that occurs in approximately 5% of women of reproductive age.

Surgical Intervention

  • Considered only as a last resort when more conservative treatments have failed
  • Conduct a preoperative trial of GnRH agonist therapy to assess benefit and to ensure tolerance to hormonal therapy
  • Patients <45 years old should be counseled to use hormonal therapy after surgery 
  • Ovary-sparing endometrial ablation and hysterectomy in women with severe PMS are not recommended

Hysterectomy with Bilateral Salpingo-oophorectomy

  • May be considered if patient failed medical therapy, requires long-term GnRH agonist therapy, or has other gynecological conditions warranting surgery
  • Has been demonstrated to exert beneficial effect on mood and physical symptoms
  • Long-term Estrogen therapy must be given to prevent Estrogen deficiency symptoms

Bilateral Oophorectomy

  • Permanent invasive method which effectively abolishes symptoms
    • Progestogen requirement with any subsequent hormonal therapy regimen after surgery may again cause PMS-like symptoms
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.